Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nonenzymatic glycation of proteins, also known as the Maillard reaction, is a spontaneous chemical process where reducing sugars react with the amino groups of proteins without the mediation of enzymes (PMID: 11730337). This reaction progresses through the formation of Schiff bases and Amadori products to create irreversible Advanced Glycation End-products (AGEs) (PMID: 15181025). AGEs accumulate on long-lived proteins like collagen and crystallin, leading to structural stiffness and functional impairment (PMID: 10410299). In chronic conditions like diabetes, accelerated glycation contributes to microvascular and macrovascular complications, including nephropathy and atherosclerosis (PMID: 15607126). Pharmacological intervention focuses on inhibiting the formation of reactive dicarbonyl intermediates or breaking existing AGE-mediated cross-links to mitigate tissue damage (PMID: 11134168). Additionally, AGEs interact with specific receptors like RAGE, triggering pro-inflammatory signaling pathways that exacerbate tissue injury (PMID: 12488523). Targeting this process is considered a potential strategy for treating age-related diseases and diabetic complications (PMID: 16318483). However, clinical success has been limited by the complexity of the reaction and the need for high specificity in scavenging reactive intermediates (PMID: 18485124).
Inhibition of reactive carbonyl species (RCS) formation, scavenging of dicarbonyl intermediates, and breaking of established protein-protein cross-links.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nonenzymatic glycation of proteins (Advanced glycation end-product formation) (AGE formation).